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ABSTRACT
We analyzed the outcomes of 24 consecutive patients aged >60 years with poor-prognosis myelodysplastic
syndrome or acute myeloid leukemia undergoing transplantation with nonmyeloablative conditioning using
fludarabine (125 mg/m2) and low-dose total body irradiation (2 Gy) followed by allogeneic peripheral blood
stem cell grafts from HLA-identical sibling donors. Graft-versus-host disease (GVHD) prophylaxis consisted
of cyclosporine and mycophenolate mofetil. The median age of the patients was 64 years (range, 60-71 years).
In addition to age, 88% of patients had 1 or more adverse biological features of the disease. With a median
follow-up of 21 months, 12 patients are alive, 11 of whom are disease free. The probabilities of 2-year overall
and progression-free survival were 52% and 44%, respectively. The cumulative probabilities of relapse and of
acute and chronic GVHD were 27%, 45%, and 74%, respectively. Nonrelapse mortality at 100 days and 2 years
was 8% and 25%, respectively. Of the 15 patients with extensive chronic GVHD, 1 patient relapsed. These data
suggest that nonmyeloablative stem cell transplantation is a feasible treatment option in patients aged >60
years with poor-prognosis myelodysplastic syndrome or acute myeloid leukemia. The reasonable disease
control with nonmyeloablative transplantation in this high-risk group of patients merits further investigation.
© 2005 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Myelodysplastic syndrome (MDS) and acute my-
loid leukemia (AML) are clonal disorders of hema-
opoietic stem cells with a median age of onset in the
ixth decade of life. The prognosis of AML in older
atients is poor, and a cure is rarely achieved with
onventional treatment approaches. Although AML is
topic of active clinical investigation, there have been
o signiﬁcant improvements in the survival of older
atients with AML [1-8]. Allogeneic stem cell trans-
lantation (SCT) is the only curative option for MDS
9] and has been shown to be of beneﬁt in some groups
f younger patients with AML [10]. For the last few p
64ears, nonmyeloablative (NMA) or reduced-intensity
ransplantation protocols have increasingly been used
o treat malignant and nonmalignant hematologic dis-
rders [11-15]. These transplantations rely predomi-
antly on a graft-versus-tumor effect rather than my-
loablation [16,17]. The major advantage of these
rotocols is the possibility of extending the procedure
o older patients and to those with comorbidities that
therwise would have precluded their candidacy for
llografting.
Despite several studies to elucidate the role of
MA or reduced-intensity transplantation in AML
nd MDS [17-27], only limited data are available in
atients aged 60 years [28,29]. Older patients with
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NMA SCT for Older Patients with MDS/AML
BML, when compared with younger patients with the
ame disease, have a poor prognosis and represent a
iscrete population in terms of disease biology, treat-
ent-related complications, and overall outcome [8].
herefore, the results of studies that do not address
ge speciﬁcally may not be applicable to older pa-
ients.
In this study, we analyzed the outcomes of 24
onsecutive patients aged 60 years with MDS or
ML undergoing NMA SCT with ﬂudarabine and
ow-dose total body irradiation using HLA-identical
ibling donors. The main outcomes of interest were
ngraftment, regimen-related toxicity, infectious
omplications, graft-versus-host disease (GVHD), and
urvival.
ATIENTS AND METHODS
atients
Between July 2000 and December 2004, 24 pa-
ients underwent NMA SCT for MDS or AML at the
rincess Margaret Hospital (University Health Net-
ork, Toronto, Ontario, Canada). The study was ap-
roved by the University Health Network Research
nd Ethics Board. Each patient and donor signed an
nformed consent. Eligibility criteria were a diagnosis
f AML or MDS, age 60 years, availability of an
LA-identical sibling donor, and the patient’s will-
ngness to undergo the transplantation. Patients were
xcluded if they had a history of invasive fungal infec-
ion or contraindication to elements of the condition-
ng regimen. All MDS patients were transfusion de-
endent and fulﬁlled the deﬁnition of intermediate or
igh risk according to International Prognostic Scor-
ng System criteria [30]. In addition to age, 88% of the
atients had 1 or more poor-prognostic biological
eatures of the disease (Table 1).
Patients with AML were treated with induction
herapy and 1 or 2 cycles of consolidation according to
reviously described institution protocols [5]. Two
ML patients referred for transplantation from out-
ide institutions had received a similar type of induc-
ion therapy with idarubicin instead of daunorubicin.
one of the MDS patients received chemotherapy for
isease control before bone marrow transplantation
BMT). Patient-, disease-, and transplant-related
haracteristics are shown in Table 1. The median age
f patients at the time of BMT was 64 years (range,
0-71 years).
onors
All patients received grafts from HLA-identical
ibling donors. Class I (A and B) and II (DRB1) HLA
yping on patients and donors was performed by low-
esolution molecular testing. The median age of do-
ors was 60 years (range, 45-73 years). The source of d
B&MTtem cells was granulocyte colony-stimulating factor
G-CSF; Neupogen; Amgen, Mississauga, Ontario,
anada)–mobilized peripheral blood mononuclear
ells in all patients except one. This donor developed
evere side effects on G-CSF and subsequently under-
ent a bone marrow harvest under general anesthesia.
he donors were given 10 g/kg G-CSF (the dose
as rounded to nearest vial size of 300 or 480 g)
ubcutaneously for 4 to 5 days, with collection on days
and 6. Only 1 collection was required in 85% of the
onors. The median numbers of CD34-positive cells
nfused amounted to 6 106/kg recipient body weight
range, 2.5-14.8  106/kg). There were 5 minor and 2
ajor ABO mismatches between donor-recipient
airs.
onditioning Regimen and GVHD Prophylaxis
The conditioning regimen comprised intravenous
IV) ﬂudarabine 25 mg/m2/d for 5 days (days 5 to
1) and single-dose total body irradiation (2 Gy) on
ay 0. Unmanipulated peripheral blood mononuclear
ells were infused on day 0. GVHD prophylaxis con-
isted of cyclosporine (CSA) and mycophenolate
ofetil (Cellcept, Roche, Mississauga, Ontario, Can-
da). CSA was started IV at 5 mg/kg/d from day 1.
he dose was titrated to maintain trough levels be-
ween 200 and 400 ng/mL. The route of administra-
ion of CSA was changed to oral as soon as tolerated.
SA taper was started on day 42 in the absence of
VHD. Mycophenolate mofetil was given at a dose of
5 mg/kg by mouth or IV twice daily (dose was
ounded to the nearest multiple of 250) from day 0 for
0 days and then stopped without taper. G-CSF was
ot routinely administered to the recipients.
upportive Care
All patients were nursed in laminar airﬂow rooms.
ntibacterial prophylaxis was given with co-trimox-
zole until neutrophil counts were 1  109/L. For
hose allergic to co-trimoxazole, ciproﬂoxacin was
ubstituted. Pneumocystis carinii prophylaxis consisted
f co-trimoxazole for at least 12 months. The time was
xtended for patients on prolonged immunosuppres-
ion. Pentamidine 300 mg every 4 weeks via aerosol
nhalation was substituted for those allergic to or un-
ble to take co-trimoxazole. Acyclovir was used twice
aily for 28 days for herpes simplex virus prophylaxis
ither at 80 mg IV or 400 mg by mouth per dose.
ntifungal prophylaxis was not routinely used. All
atients were supported with irradiated and leukode-
leted blood products. Cytomegalovirus (CMV)–neg-
tive blood products were used for CMV-seronegative
ecipients. Monitoring for CMV was performed in
t-risk patients (seropositive recipients or donors) by
p65 antigen testing on a weekly basis for the ﬁrst 100
ays and subsequently on clinic visits up to 1 year or
765
Table 1. Patient-, Disease-, and BMT-Related Characteristics
Patient
No.
Patient
Age at
BMT
(y)/Sex
Donor
Age
(y)/Sex Diagnosis Cytogenetics
Pre-BMT
Therapy
Disease
Status at
BMT High-Risk Features
Acute
GVHD
Chronic
GVHD
Status at Last
Follow-Up
Follow-Up
(d)
1 65/F 66/M AML Suboptimal D  A  1
D  mHiDAC
 2
CR1 High WBC count at
diagnosis (47 
109/L)
NE NE Died (sepsis) 12
2 66/M 62/M Relapsed
AML
46, XY, del (20) (q11.2) NOVE-HiDAC
 1
CR 2 Relapsed after
autograft for AML
Grade II Extensive Died in remission
(sudden
cardiac death)
1213
3 62/M 48/M AML-MDS Diploid D  A  1
D mHiDAC
 1
CR 1 Preceding MDS No No Died (disease
relapse)
205
4 64/F 53/F tAML
(relapsed)
Not done D  A  1 CR 2 Therapy-related AML
(breast cancer
treated with CT)
No Extensive Died in remission
(relapse of
breast cancer)
283
5 63/F 60/M AML Suboptimal D  A  1
D  mHiDAC
 2
CR1 — No No Died (disease
relapse)
1158
6 67/M 73/M AML-MDS Diploid Ida  A  1 CR 1 Preceding MDS No Extensive Died (GVHD) 122
7 63/M 49/F AML 45, X-Y D  A  1
D  mHiDAC
 2
CR 1 — Grade III Extensive Died (GVHD) 282
8 63/M 45/F AML-MDS 46, XY, der(17)t(11;17)
(q1 3;p13)
D  A  1 MDS phase,
blasts <5%
Preceding MDS,
granulocytic
sarcoma
No NE Died (disease
relapse)
66
9 67/M 54/F AML-MDS 4446, XY, add(2)(p21),
del(5)(q15q33), 7,
12, 13, add(16)(q24),
19, 24mar[cp12]/
46,XY[6]
AMSAA  1
AMSA 
mHiDAC  1
CR 1 Preceding MDS,
adverse-risk
karyotype
Grade II No Died (disease
relapse)
191
10 67/M 65/F Relapsed
AML
Diploid D  A  1 CR 2 Second remission Grade III Extensive Died in remission
(Parkinson
disease)
499
11 68/M 65/M AML Suboptimal D  A  1
NOVE-HiDAC
 1
AMSA 
mHiDAC  1
CR 1 CR after 2 courses of
induction therapy
No Extensive Alive, in
remission
748*
12 61/M 57/M AML 46, XY[7]/, 47, XY,
8[12]
Ida  A  1
Ida  mHiDAC
 2
CR 1 Poor-risk karyotype No Extensive Alive, remission 465*
13 71/M 68/M AML Diploid AMSA  A  1
AMSA 
mHiDAC  1
CR 1 Preceding MPD Grade II Extensive Alive, in
remission
329*
14 63/F 48/M AML 46, XX, add(4)(q3?5)[13] D  A  2 CR 1 — NE NE Died (VOD) 20
V
.G
upta
et
al.
766
15 60/F 57/M tAML Diploid DA  1
NOVE-HiDAC
 1
CR 1 Therapy-related AML
(breast cancer
treated with CT
and RT), CR 1 with
2 courses of
induction
No No Alive, in
remission
122*
16 65/F 63/F tMDS Diploid Untreated RAEB (10%
blasts)
Therapy-related MDS
(cyclophosphamide
for Wegner
granulomatosis)
No Extensive Alive, in
remission
1383*
17 65/F 45/M MDS 4347, X, add(X)(p22),
add(1)(p36),
del(5)(q13),
add(8)(p23), 10, t(12;
15)(q10;q10), add(17)
(p11), add(17)(q25),
20, mar1,
mar2[cp10]
Untreated RAEB (19%
blasts)
High-risk IPSS No No Died (disease
progression)
128
18 68/M 64/F MDS Diploid Untreated RAEB (10%
blasts)
Intermediate-risk
IPSS
Grade II Extensive Alive, in
remission
1294*
19 66/F 47/F Relapsed
AML
Diploid ME  1 15% blasts Active disease No Extensive Alive, in
remission
548*
20 60/F 58/F tMDS 46, XX, 3, der(5)t(3;
5)(q13.2;q15), 8,
del(9)(q22q32)[20]
Untreated RA with
multilinear
dysplasia
Previous
autotransplantation
for relapsed HD,
adverse karyotype
Grade II Extensive Alive, in
remission
911*
21 65/M 58/F MDS 45, XY, 7[20] Untreated RAEB (18%
blasts)
Adverse karyotype,
high-risk IPSS
No Extensive Alive, in
remission
391*
22 62/F 60/F tMDS 45, XX, 7[10]/46, XX[2] Untreated RA with
trilineage
dysplasia
Therapy-related MDS
(breast cancer
treated with CT
and RT), adverse
karyotype
Grade III Extensive Alive, in
remission
315*
23 62/M 60/M MDS 4547, X, Y, 8[cp11]/
45, XY[3]
Untreated RA Intermediate-risk
IPSS
No No Alive, in
remission
245*
24 60/F 61/M tMDS 4445, XX, 3, der(5)t(5;
15)(q13;q15), der(6)t(3;
6)(q13.2;p23)dup(6)
(p21.1p23), 15, mar
[cp6]/46, XX[5]
Untreated RA with
trilineage
dysplasia
Therapy-related MDS
(endometrial
cancer treated with
CT and RT),
adverse karyotype
Grade III Extensive Alive (disease
relapse)
141*
BMT indicates bone marrow transplantation; M, male; F, female; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; tAML, therapy-related AML; tMDS, therapy-related MDS; D,
daunorubicin; A, cytarabine; mHiDAC, modiﬁed high-dose cytarabine; Ida, idarubicin; AMSA, amsacrine; NOVE-HiDAC, mitoxantrone, etoposide, and high-dose cytarabine; M, mitoxantrone; E,
etoposide; CR, complete remission; RAEB, refractory anemia with excess blasts; RA, refractory anemia; MPD, myeloproliferative disorder; CT, chemotherapy; RT, radiotherapy; IPSS, International
Prognostic Scoring System; WBC, white blood cell; GVHD, graft-versus-host disease; NE, not evaluable; HD, Hogkin disease; VOD, veno-occlusive disease.
*Alive.
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7ccording to clinical indications. Preemptive therapy
ith IV ganciclovir, delivered by ambulatory infusion
ump, was started at antigen levels 1/100 000 cells
nd was continued until 2 consecutive negative levels
ere taken a week apart.
efinitions and Evaluation of Response
Myeloid and platelet engraftment were deﬁned as
he ﬁrst of 3 consecutive days with an absolute neu-
rophil count0.5 109/L and the ﬁrst of 7 days with
nsupported platelet counts of 20  109/L. Patients
ere evaluable for engraftment if they survived at least
1 days after BMT. Donor cell engraftment was as-
essed by chimerism studies on unsorted peripheral
lood on day 60 and as clinically indicated according
o the methods previously described [31].
Patients who survived 14 and 100 days after
ransplantation were evaluable for acute and chronic
VHD, respectively. The diagnosis of GVHD was
ased on clinical criteria with histopathologic conﬁr-
ation whenever possible. The severity of acute and
hronic GVHD was scored according to previously
eﬁned criteria [32,33]. For study evaluation, the
ighest grade of GVHD was taken. In addition, the
eriousness of GVHD was scored retrospectively ac-
ording to the criteria recently described by Flowers
t al. [34]. Regimen-related toxicity was graded ac-
ording to the Bearman criteria [35]. Progression-free
urvival was calculated from the date of BMT to re-
apse or progression of disease, death from any cause,
r last follow-up. Overall survival was calculated from
he date of BMT to death or last follow-up.
tatistical Analysis
Data were updated as of May 1, 2005. Results were
eported as proportions and 95% conﬁdence intervals
CIs). The Kaplan-Meier method was used to estimate
urvival [36]. The cumulative incidences of relapse
nd of acute and chronic GVHD were estimated with
he Cmprsk package in R software (The R Founda-
ion, Vienna, Austria). The risk of dying from any
ause was treated as a competing event [37]. All anal-
ses were performed with SAS 8.01 (SAS Institute,
ary, NC).
ESULTS
Patient-, disease-, and transplant-related charac-
eristics are shown in Table 1. The median time from
iagnosis to BMT was 5 months (range, 2-55 months).
ematopoietic Recovery and Donor Cell
ngraftment
Two patients died before hematopoietic recovery.
ive patients’ neutrophil counts never decreased 0.5
109/L, and 8 patients’ platelet counts never de- t
68reased 20  109/L. For patients with neutrophil
ounts 0.5  109/L and platelets 20  109/L, the
edian time to neutrophil and platelet recovery was
3 days (range, 7-27 days) and 12 days (range, 10-34
ays), respectively. The median length of hospital stay
or BMT was 17 days (range, 10-26 days).
Of the 22 evaluable patients, 20 had chimerism
valuations on unsorted peripheral blood cells on day
0. Fourteen patients demonstrated predominantly
onor engraftment, deﬁned as 90% donor cells. Of
he 6 patients with mixed chimerism (90% donor
ngraftment), 3 patients received donor leukocyte in-
usions. One of these patients changed to predomi-
antly donor chimerism, and the other 2 relapsed.
hree patients were not given donor leukocyte infu-
ions because of active GVHD (n  1), hematologic
elapse with bulky disease (n  1), and donor unavail-
bility (n 1). There seemed to be a relationship with
onor chimerism and relapse risk. Four of the 6 pa-
ients with 90% donor chimerism relapsed, com-
ared with 1 of 14 patients with90% donor chimer-
sm.
egimen-Related Toxicity
Regimen-related toxicities in the ﬁrst 100 days
ere grade 1 mucositis (n  2), grade 1 renal impair-
ent (n  1), and grade 4 veno-occlusive disease (n 
). No risk factors for veno-occlusive disease could be
dentiﬁed in this patient on detailed evaluation. In
ddition, 1 patient developed optic neuritis, which
esponded to steroids.
nfectious Complications
Culture-positive bacterial infections were ob-
erved in 9 (37%) patients in the ﬁrst 100 days of
ransplantation. One patient died of sepsis related to a
oagulase-negative staphylococcal infection. No prob-
ble or proven fungal infections were seen. Six (37%)
f 16 CMV-positive recipients experienced reactiva-
ion of disease, 3 in the ﬁrst 100 days of transplanta-
ion and 3 beyond 100 days of transplantation. None
f the patients developed CMV disease. No CMV
eactivation was observed in 3 CMV-seronegative re-
ipients whose donors were seropositive. Other infec-
ious complications were varicella zoster (n  1) and
erpes simplex causing keratitis (n  1) or mucositis
n  1).
raft-versus-Host Disease
Of the 22 evaluable patients, 9 developed acute
VHD grade II (n  5) and grade III (n  4). One
atient (patient 24) had steroid-refractory acute
VHD. Of the 21 patients evaluable for chronic
VHD, 15 patients had extensive GVHD. Among the
atients with chronic GVHD, 1 patient relapsed (pa-
ient 24). This patient had therapy-related MDS with
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NMA SCT for Older Patients with MDS/AML
Bultiple numeric and structural chromosomal abnor-
alities. The cumulative incidences of grade II/III
cute and chronic GVHD were 45% (95% CI, 28%-
3%) and 74% (55%-98%), respectively (Figure 1).
one of the patients developed grade IV GVHD. The
eriousness of GVHD (acute or chronic) was assessed
etrospectively on the basis of a recent study from the
eattle team [34], and 7 patients (44%) were found to
ave serious GVHD. The serious GVHD in these
atients resulted in death (n  2), prolonged hospi-
alization (n  2), and disability affecting activities of
aily living (n  3).
urvival
With a median follow-up of 21 months (range,
-46 months), 12 patients are alive, of whom 11 are
isease free. The 2-year progression-free and overall
urvival rates were 44% (95% CI, 23%-82%) and
2% (95% CI, 34%-81%), respectively (Figure 2). A
lateau in the survival curves has not been observed.
elapses were seen in 6 patients, thus resulting in a
umulative risk of 27% (95% CI, 13%-56%). Twelve
atients died. The causes of death were identiﬁed as
reatment-related mortality (n  4: sepsis, n  1;
eno-occlusive disease, n  1; and GVHD, n  2),
elapse (n  5), and unrelated causes (n  3: Parkin-
on disease, n  1; sudden cardiac death, n  1; and
elapse of primary nonhematologic malignancy, n 
). Treatment-related mortality at 100 days and 2
ears was 8% and 17%, respectively. Overall nonre-
apse mortality at 100 days and 2 years was 8% and
5%, respectively.
ISCUSSION
Limited data are available on the outcome of
MT in patients aged 60 years with AML or MDS.
igure 1. Cumulative incidence of chronic GVHD (the risk of
ying from any cause was treated as a competing event).recent study from Seattle reported the experience of C
B&MT2 older patients (60 years) with hematologic ma-
ignancies who underwent transplantation after my-
loablative conditioning [38]. Of the 41 patients with
DS (n  35) or AML (n  6) in the study, 14
urvived. Although it is difﬁcult to make interstudy
omparisons between patients treated with myeloab-
ative versus NMA protocols, the data from our study
ook encouraging. Our study shows that sustained
ngraftment is achievable in this group of patients
ith modest treatment-related mortality and reason-
ble disease control. Our study cohort included 6
atients with therapy-related MDS (n 4) or AML (n
2); 4 of these patients are currently alive and in
emission (patients 15, 16, 20, and 22). Of the 11 AML
atients who underwent transplantation in ﬁrst remis-
ion, 4 died in remission of transplant-related compli-
ations, and 3 relapsed. All 3 AML patients who un-
erwent transplantation in second remission stayed in
emission but died of unrelated causes at days 1213
patient 2), 283 (patient 4), and 499 (patient 10). Two
f the 8 patients with MDS relapsed, and there were
o treatment-related deaths. As highlighted in Table
, 88% of our patients had 1 or more poor-prognostic
iological risk factors for which long-term disease
ontrol is rarely achieved even with intensive conven-
ional chemotherapeutic options. As a result of the
imited sample size, we were unable to evaluate the
ffect of various prognostic factors on outcome.
The cumulative incidence of chronic GVHD was
4% in our study. Only 1 of the patients with exten-
ive chronic GVHD relapsed. However, 5 patients
ied in remission: 2 deaths were due to direct conse-
uences of GVHD and 3 to unrelated causes. The
easonable disease control with minimal conditioning
igure 2. Kaplan-Meier plots of progression-free and overall sur-
ival of older patients with MDS or AML undergoing nonmyeloa-
lative stem cell transplantation. The 2-year progression-free and
verall survival rates were 44% (95% CI, 23%-82%) and 52% (95%
I, 34%-81%), respectively.
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7uggests a graft-versus-leukemia effect in these pa-
ients.
One of the major limitations of the currently used
hronic GVHD classiﬁcation is an inability to de-
cribe the effect of GVHD on overall quality of life.
herefore, we also scored the seriousness of GVHD
etrospectively according to recently described criteria
y Flowers et al. [34] from Seattle. Of all patients with
cute and chronic GVHD in our study, 44% had
erious GVHD. A previous study compared the sever-
ty, timing, and quality of GVHD among recipients of
yeloablative and NMA transplantations. The inci-
ence of chronic GVHD in 2 study cohorts was not
igniﬁcantly different [39]. It is possible that the high
ncidence of serious GVHD observed in our study is
elated to advanced age, a concern that should be
ddressed by future studies with prospective analysis
n quality-of-life issues. Selective T-cell depletion and
vailability of agents such as antithymocyte globulin,
lemtuzumab, and anti-CD45 monoclonal antibodies
or transplantation protocols may offer the possibility
f decreasing GVHD without compromising the
raft-versus-leukemia effect [19,40-42].
The pattern of infectious complications (particu-
arly CMV reactivation) in our patient cohort seems to
e comparable to those in studies that have evaluated
educed-intensity or myeloablative transplantations in
elatively younger patients [43-45]. A major hurdle in
he use of BMT from sibling donors is its limited
pplicability in older patients. It is more difﬁcult to
nd suitable sibling donors, because the donors are
sually old and often have comorbidities that exclude
hem from stem cell donation [46]. The median age of
onors in our study was 60 years. In our experience,
he chances of ﬁnding a suitable sibling donor for a
atient with acute leukemia above the age of 60 years
re substantially lower compared with the younger
opulation. Only 10 (14%) sibling donors could be
dentiﬁed from a cohort of 70 patients between the
ges of 60 and 70 years treated for AML with intensive
herapy at our center. In comparison, the chance of
nding an HLA-identical sibling donor for patients
ounger than 55 years was 42% in a previous study
rom our center [47]. To increase the applicability, the
ole of unrelated donors needs to be explored for this
atient population. Preliminary observations on a
mall number of patients suggest that this may be
easible [29,48].
A recent study from the International Bone Mar-
ow Transplant Registry examined the timing of my-
loablative SCT fromHLA-identical sibling donors in
atients with MDS [49]. This study showed that de-
ayed transplantation for low-risk MDS was associated
ith improved outcome. Conversely, transplantation
n early disease is associated with a lower risk of
elapse. Although this is speculative at present, a sig-
iﬁcant reduction in transplant-related mortality by
70sing NMA SCT may allow the possibility of using
ransplant-related options early in the disease course.
ewer agents such as azacytidine and decitabine have
een shown to improve marrow function and quality
f life and to delay leukemic transformation in pa-
ients with MDS [50-52]. Inclusion of these agents in
he NMA SCT protocols may further help to improve
he efﬁcacy of these protocols in high-risk patients.
he overall beneﬁt of these transplantations when
ompared with conventional chemotherapy options is
ot clear at present. This question is being addressed
n an ongoing prospective international study based
n genetic randomization involving multiple institu-
ions in Sweden, Canada, and Germany for patients
ith AML who are older than 50 years.
In summary, we conclude that donor engraftment
s feasible in older patients by using minimal condi-
ioning and can potentially offer reasonable disease
ontrol for some patients with poor-prognosis MDS
r AML. Although the relapse rate in patients with
xtensive chronic GVHD was low, the effect of
VHD was debilitating in some patients. These data
uggest that NMA conditioning merits further explo-
ation in older patients with MDS or AML. Study
esigns should considers the concerns related to seri-
us GVHD.
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